Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)				1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 06, 2023 USD ($) shares	Sep. 05, 2023 USD ($)	Jun. 10, 2021 shares	Nov. 30, 2021 USD ($) stockholder shares	Jun. 30, 2024 USD ($) non-employeeDirector tradingDay $ / shares shares	Jun. 30, 2023 USD ($) officer $ / shares shares	Mar. 31, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense					$ 21,577,000	$ 51,100,000
Weighted-average grant date fair values of options granted (in usd per share) | $ / shares					$ 0	$ 1.43
Intrinsic value of vested options exercised					$ 0	$ 200,000
Unrecognized stock-based compensation cost					$ 22,200,000
Weighted average period over which unrecognized compensation is expected to be recognized					2 years 1 month 6 days
Granted (in shares) | shares					0
Shares reserved for future issuance (in shares) | shares					223,027,929		238,918,589
Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period				4 years
Common stock granted subject to vest, Weighted average grant date fair value				$ 43,900,000
Former officers terminated | officer						1
Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Tax benefit recognized from stock option exercises					$ 0	$ 0
Outstanding stock options | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Outstanding stock options | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years
Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted (in shares) | shares					42,032,239
Weighted average period over which unrecognized compensation is expected to be recognized					2 years 1 month 6 days
Unrecognized stock-based compensation cost					$ 90,100,000
Former Lemonaid Officer | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation cost					0
Former Lemonaid Officer | Lemonaid Health, Inc. | General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense					$ 0	24,700,000
Former Lemonaid Officer | Unvested restricted stock units | Lemonaid Health, Inc. | General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense						22,000,000.0
Class A Common Stock | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock granted subject to vest (in shares) | shares				3,747,027
Class A Common Stock | Former Lemonaid Officer | Lemonaid Health, Inc.
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Former stockholders who were granted shares | stockholder				2
A&R Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Percentage of shares automatically added annually	5.00%	3.00%
Non-employee directors, electing to convert cash compensation to RSUs | non-employeeDirector					4
Non-employee directors, electing to defer settlement of RSUs | non-employeeDirector					2
A&R Plan | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation terms of award	Options have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
Share-based payment award, expiration period	10 years
Number of shares of common stock received for each option exercised	1
A&R Plan | Outstanding stock options | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair value of shares	100.00%
A&R Plan | Unvested restricted stock units | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
A&R Plan | Unvested restricted stock units | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years
A&R Plan | Director | Share-Based Payment Arrangement, Nonemployee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual compensation limit	$ 400,000	$ 300,000
A&R Plan | Class A Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares authorized (in shares) | shares	75,000,000
Annual Incentive Plan | Unvested restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Performance period							1 year
Granted (in shares) | shares					12,144,435
Total stock-based compensation expense					$ 4,100,000	$ 4,400,000
Other current liabilities for awards					$ 4,100,000		$ 6,500,000
Annual Incentive Plan | Class A Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Days preceding date of payment | tradingDay					20
ESPP | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock issued and outstanding, percentage			1.00%
Potential annual increase in shares reserved for future issuance (in shares) | shares			5,000,000
ESPP | Employee Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
ESPP concurrent offering period					12 months
ESPP successive purchase period					6 months
ESPP | Class A Common Stock | Outstanding stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares reserved for future issuance (in shares) | shares			11,420,000
Issuance of common stock under employee stock purchase plan (in shares) | shares					0	0